Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Ian Frank, Jonathan D. Fuchs et al.|The Journal of Infectious Diseases|2013Cited by 198
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84
Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C<i>gag</i>Vaccine in Healthy HIV-1-Uninfected AdultsMargaret Wecker, Donald S. Burke, Peter B. Gilbert et al.|Clinical and Vaccine Immunology|2012Cited by 68
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Bethany Coomes, Christopher B. Hurt et al.|The Lancet HIV|2024Cited by 12
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest PeriodPaul Spearman, Georgia D. Tomaras, David C. Montefiori et al.|The Journal of Infectious Diseases|2019Cited by 8